Monitor for additional insider buying from C-suite executives to confirm conviction. The Q2 earnings beat and reaffirmed guidance provide a supportive backdrop, but the flat case volume and declining EBITDA warrant caution.
Price Chart
Executive Summary
Director Teresa DeLuca purchased 21,250 shares of Surgery Partners (SGRY) for ~$305K in two open-market transactions on August 18, 2026, at ~$14.33-$14.35 per share. This conviction buy follows the company's Q2 2026 earnings beat (adjusted EPS $0.10 vs. $0.07 consensus) reported 8 days prior, where revenue grew 2.7% YoY to $848.9M but Adjusted EBITDA declined to $125.2M from $129.0M.
Key Financial Metrics
Key Facts
- Director Teresa DeLuca purchased 21,250 shares total for ~$305K on 2026-08-18 at ~$14.33-$14.35/share.
- Purchase follows Q2 2026 earnings beat (adj. EPS $0.10 vs. $0.07 consensus) reported on 2026-08-10.
- Q2 revenue was $848.9M (+2.7% YoY), same-facility revenue +5.0%, but Adjusted EBITDA declined to $125.2M from $129.0M.
- Full-year guidance reaffirmed: revenue $3.35B-$3.45B, Adj. EBITDA $530M+.
- Market cap is $1.8B; the $305K purchase represents ~0.017% of market cap — below the 0.1% threshold for materiality.
Financial Impact
Director invested ~$305K at ~$14.34/share, representing 0.017% of $1.8B market cap — a small but genuine conviction signal.
Risk Factors
- Insider purchase is small relative to market cap (0.017%) and may not signal broad conviction.
- Q2 Adjusted EBITDA declined YoY despite revenue growth, indicating margin pressure.
- Flat total case volume suggests limited organic growth momentum.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001638833-26-000081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | DEFA14A | $23.20 | awaiting T+5 | — | $23.36 (+0.69%) |
Oct 26, 2026 1d ago | DEFA14A | $23.32 | awaiting T+5 | — | $23.36 (+0.17%) |
Oct 26, 2026 1d ago | SC 13D/A | $23.25 | awaiting T+5 | — | $23.36 (+0.47%) |
Oct 26, 2026 1d ago | DEFA14A | $23.25 | awaiting T+5 | — | $23.36 (+0.47%) |
Oct 26, 2026 1d ago | 8-K | $23.25 | awaiting T+5 | — | $23.36 (+0.47%) |
Oct 13, 2026 14d ago | SC 13G | $14.83 $15.40 | ▲ +3.84% | ▲ +3.39% | $23.36 (+57.52%) |
Sep 17, 2026 5w ago | 8-K | $13.35 $14.20 | ▲ +6.37% | ▲ +5.77% | $23.36 (+74.98%) |
Sep 17, 2026 5w ago | Press Release | $13.35 $14.20 | ▲ +6.37% | ▲ +5.52% | $23.36 (+74.98%) |
Aug 20, 2026 9w ago | Insider Buy | $14.52 $13.69 | ▼ −5.72% | ▼ −6.19% | $23.36 (+60.88%) |
Aug 10, 2026 11w ago | 8-K | $15.95 $14.36 | ▼ −9.97% | ▼ −9.92% | $23.36 (+46.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers